Discovery improves profiling of AML patients for targeted therapies
Testing for DNMT3A mutations in FLT3-ITD subgroup of AML patients at the point of diagnosis and post-chemotherapy could improve treatment and predict chances of relapse and survival rates respectively
Jul 11, 2016
0
1